Tim Smith

These findings from the phase 3 STRATUM trial suggest significant DLQI score improvements as early as the second week of treatment with roflumilast foam.

In this interview, Bunick spoke about the contents of his Fall Clinical Dermatology presentation specifically regarding mechanisms of action and safety of systemic therapies.

In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.

In this interview, Kwatra highlighted several key takeaways from his talks on prurigo nodularis, atopic dermatitis, and itch at the Fall Clinical Dermatology Conference.

These long-term extension trial data from ADORING 3 highlight tapinarof cream’s efficacy in adults and children aged 2 years and older with atopic dermatitis.

In this interview segment, Del Rosso highlighted his Fall Clinical presentation takeaways covered in the talk ‘What’s New in the Medicine Chest - Part 2.’

These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.

These data were presented at Fall Clinical, highlighting the reductions in Eczema Area and Severity Index scores and the overall long-term safety profile of tralokinumab-ldrm.

These data demonstrated guselkumab’s success for the majority of patients with low body surface area (BSA) moderate plaque psoriasis and special site involvement.

This talk was titled ‘Heard About It, Did It, Now it's Part of My Practice,’ during which Swanson highlighted creative options for conditions such as guttate psoriasis and pyogenic granulomas.

In the first part of his Fall Clinical presentation on new topical medications, Del Rosso discusses new therapies available for use among dermatologists.

At the Fall Clinical Dermatology conference, Chovatiya presented on chronic hand eczema and facts about its pathophysiology, diagnosis, and management.

In this interview with Chovatiya, he highlights some of the elements of the presentations being given at the Fall Clinical Dermatology conference in Las Vegas.

The drug’s favorable risk-benefit profile and sustained efficacy through 76 weeks was highlighted in this analysis’s findings.

This overview highlights our upcoming conference coverage at the Fall Clinical Dermatology Conference in Las Vegas.

This analysis reconfirms the efficacy of dupilumab using a single-center design, a large sample size, and patients with chronic hand eczema.

In the most recent Lungcast, Rachel Eddy, PhD, joined host Al Rizzo, MD, to speak to listeners about the current and future uses of AI in lung imaging.

These data suggest more immediate benefits to alitretinoin, though ultraviolet therapy was shown to be cost-effective after 10 years of use.

Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.

In this cohort study, the drug survival rates of methotrexate, cyclosporine A, and dupilumab for adolescents with eczema were assessed along with reasons for discontinuation.

In this single center analysis, investigators highlighted results of dupilumab treatment after 3 years among patients with moderate-to-severe eczema.

This analysis aligns with previous research into dose optimization of biologics for psoriasis, affirming enhancement of outcomes without compromising patient safety.

This analysis was conducted to evaluate whether genetic risk of hidradenitis suppurativa was linked to greater risk of future cardiometabolic disease.

This review compares the clinical and real-world outcomes of drugs such as mepolizumab versus drugs such as benralizumab for severe eosinophilic asthma.

This review provides an overview of current data on immune development and risk factors for preterm-born infant development of respiratory infections and wheezing.

These data on metabolic dysfunction-associated steatotic liver disease provide information on the economic burden among high-risk patients.

The Accure Laser System is indicated for long term treatment of patients known to have mild to severe inflammatory acne vulgaris.

This analysis may help identify at-risk patients of liver enzyme elevation following sustained virologic response among individuals with hepatitis C virus infection.

In this analysis, the investigators sought to assess the efficacy and safety of risankizumab compared to placebo for patients with palmoplantar psoriasis.

These data resulted from comparisons of the time to onset of action among various available systemic medications for those with plaque psoriasis.